Literature DB >> 24627587

Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.

Full-Young Chang1.   

Abstract

Irritable bowel syndrome (IBS) is common in the society. Among the putative pathogeneses, gut dysmotility results in pain and disturbed defecation. The latter is probably caused by the effect of abnormal gut water secretion. The interaction between abnormal gas accumulation, abdominal pain and bloating remains controversial. Visceral hypersensitivity and its modification along with the central transmission are the characteristics of IBS patients. The identification of biologic markers based on genetic polymorphisms is undetermined. Imbalanced gut microbiota may alter epithelial permeability to activate nociceptive sensory pathways which in turn lead to IBS. Certain food constituents may exacerbate bowel symptoms. The impact of adult and childhood abuses on IBS is underestimated. Using the concept of biopsychosocial dysfunction can integrate multidimensional pathogeneses. Antispasmodics plus stool consistency modifiers to treat the major symptoms and defecation are the first-line drug treatment. New drugs targeting receptors governing bowel motility, sensation and secretion can be considered, but clinicians must be aware of their potential serious side effects. Psychiatric drugs and modalities may be the final options for treating intractable subjects. Probiotics of multi-species preparations are safe and worth to be considered for the treatment. Antibiotics are promising but their long-term safety and effectiveness are unknown. Diet therapy including exclusion of certain food constituents is an economic measure. Using relatively safe complementary and alternative medicines (CAMs) may be optional to those patients who failed classical treatment. In conclusion, IBS is a heterogeneous disorder with multidimensional pathogeneses. Personalized medicines with multidisciplinary approaches using different classes of drugs, psychiatric measures, probiotics and antibiotics, dietary therapy, and finally CAMs, can be considered.

Entities:  

Keywords:  Antispasmodics; Biopsychosocial dysfunction; Comorbidity; Genetics; Irritable bowel syndrome; Microbiota; Probiotics; Visceral hyperalgesia

Mesh:

Substances:

Year:  2014        PMID: 24627587      PMCID: PMC3949260          DOI: 10.3748/wjg.v20.i10.2499

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  180 in total

Review 1.  Twin studies of pain.

Authors:  C S Nielsen; G P Knudsen; Ó A Steingrímsdóttir
Journal:  Clin Genet       Date:  2012-08-13       Impact factor: 4.438

Review 2.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

Review 3.  Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date.

Authors:  E M M Quigley; B Flourie
Journal:  Neurogastroenterol Motil       Date:  2007-03       Impact factor: 3.598

Review 4.  Acupuncture for irritable bowel syndrome: systematic review and meta-analysis.

Authors:  Eric Manheimer; L Susan Wieland; Ke Cheng; Shih Min Li; Xueyong Shen; Brian M Berman; Lixing Lao
Journal:  Am J Gastroenterol       Date:  2012-04-10       Impact factor: 10.864

Review 5.  Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation.

Authors:  Shin Fukudo
Journal:  J Gastroenterol       Date:  2007-01       Impact factor: 7.527

Review 6.  Irritable bowel syndrome--diarrhoea.

Authors:  Arnold Wald
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-10       Impact factor: 3.043

Review 7.  Motility disorders of the colon and rectum.

Authors:  Beatriz Gras; Suma Magge; Andrea Bloom; Anthony Lembo
Journal:  Curr Opin Gastroenterol       Date:  2013-01       Impact factor: 3.287

8.  IgG-based elimination diet in migraine plus irritable bowel syndrome.

Authors:  Elif Ilgaz Aydinlar; Pinar Yalinay Dikmen; Arzu Tiftikci; Murat Saruc; Muge Aksu; Hulya G Gunsoy; Nurdan Tozun
Journal:  Headache       Date:  2012-12-06       Impact factor: 5.887

Review 9.  Genetic determination of irritable bowel syndrome.

Authors:  Cristina Hotoleanu; Radu Popp; Adrian-Pavel Trifa; Laurentiu Nedelcu; Dan-L Dumitrascu
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

10.  Serotonin transporter promoter variant: Analysis in Indian IBS patients and control population.

Authors:  Arbab Sikander; Satya Vati Rana; Saroj Kant Sinha; Kaushal Kishor Prasad; Sunil K Arora; Sanjeev Kumar Sharma; Kartar Singh
Journal:  J Clin Gastroenterol       Date:  2009 Nov-Dec       Impact factor: 3.062

View more
  12 in total

1.  Common GI Drug Interactions in the Elderly.

Authors:  Marina Kim; Aamir Dam; Jesse Green
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

Review 2.  Treatment of irritable bowel syndrome in China: a review.

Authors:  Chun-Yan Li; Shu-Chuen Li
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

Review 3.  Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.

Authors:  Paula Mosińska; Jakub Fichna; Martin Storr
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

4.  Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome.

Authors:  Feng-yun Wang; Min Su; Yong-qiu Zheng; Xiao-ge Wang; Nan Kang; Ting Chen; En-lin Zhu; Zhao-xiang Bian; Xu-dong Tang
Journal:  Acta Pharmacol Sin       Date:  2015-05-11       Impact factor: 6.150

5.  Visceral and somatic hypersensitivity, autonomic cardiovascular dysfunction and low-grade inflammation in a subset of irritable bowel syndrome patients.

Authors:  Liang Liu; Bei-ni Liu; Shuo Chen; Miao Wang; Yang Liu; Yan-li Zhang; Shu-kun Yao
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

6.  Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety.

Authors:  Ling Lan; Yu-Long Chen; Hao Zhang; Bai-Ling Jia; Yan-Jun Chu; Jin Wang; Shi-Xiao Tang; Guo-Dong Xia
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 7.  Role of environmental pollution in irritable bowel syndrome.

Authors:  Mateusz Marynowski; Aleksandra Likońska; Hubert Zatorski; Jakub Fichna
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

8.  The comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran.

Authors:  Mohamadreza Yazdani; Amirhossein Aramesh; Rahmatollah Rafiei; Hamed Daghaghzadeh; Peyman Adibi
Journal:  Adv Biomed Res       Date:  2016-11-28

Review 9.  Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide.

Authors:  Apoorva Krishna Chandar
Journal:  Int J Gen Med       Date:  2017-10-31

10.  Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial.

Authors:  Qian Li; Bei-Ping Zhang; Shao-Gang Huang; Wen-Wei Ouyang; Jian-Hui Xie; Ze-Huai Wen; Xiao-Bo Yang
Journal:  Trials       Date:  2018-07-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.